Award Recognizes Excellence in Financial/Investor Relations
Boston, MA- August 22, 2018- LaVoieHealthScience (LHS), an integrated investor and public relations agency focused on advancing health and science innovations, has been selected as a PRNews Platinum Award finalist in the Investor/Financial Relations Campaign category. The awards ceremony will take place on September 21st, 2018 at the Grand Hyatt in NYC. The nomination is for the agency’s work on behalf of its client Ampio Pharmaceuticals, a development stage biopharmaceutical company focused on novel therapies to treat common inflammatory conditions.
LaVoieHealthScience developed a multi-faceted financial/investor relations integrated communications plan for Ampio to optimize the impact of the release of pivotal Phase 3 data results for their leading drug candidate Ampion™, a treatment for severe osteoarthritis of the knee.
The campaign included traditional, paid and social media, and was designed to reach all stakeholders with concise and compelling messaging for a broad audience. This included patients, physicians, strategic partners and investors. The campaign also included a press release that was offered to reporters under embargo, as well as a post-distribution follow-on campaign that targeted the full range of national, local, business, trade and orthopedic outlets. The campaign included sponsored print and radio content.
“LaVoieHealthScience is thrilled to be selected as a finalist for the PRNews Platinum Awards for our client Ampio Pharmaceuticals,” said Donna L. LaVoie, President & CEO, LaVoieHealthScience. “This is a stand-out example of how to gain maximum visibility through an integrated campaign using paid, earned and social media.”
The PRNew’s Award follows LaVoieHealthScience taking home the Silver Bell Ringer Award in the Investor/Financial Relations Campaign category from the Publicity Club of New England at the 50th Annual Bell Ringer Awards in Boston. This honor was also for their work with Ampio Pharmaceuticals in the same category as their newest nomination.
LaVoieHealthScience partners with leading health and science brands to build value for their companies, attract capital and reach key stakeholders through integrated communications and marketing. The firm provides public relations, investor relations and marketing and digital communications to build recognition and increase sales and value for health science innovations. The agency has received over 30 awards over the past seven years in recognition of the work it has done for its health and science industry-leading clients and was inducted in the 2018 Inc. 5000 Hall of Fame List of Fastest Growing Private Companies. LaVoieHealthScience represents leaders such as, Emmaus Life Sciences, Landos Biopharma, LEO Science & Tech Hub, Life Sciences Corridor, NewLink Genetics, Newron Pharmaceuticals, Origenis GmbH, PathMaker Neurosystems, Scioto Biosciences, Symbiotix Biotherapies, Triumvira Immunologics, XenoTherapeutics, Xontogeny LLC, and other emerging health and science companies.